A world-first study led by Austin Health's clinician-researchers has demonstrated the feasibility and safety of using ...

Radiotherapy professionals from 10 Asian countries have completed an IAEA training course on ultra-hypofractionated radiotherapy — a way of treating cancer with ionizing radiation that reduces ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

IAEA radiation oncologist Soha Salem leading a session on ultra-hypofractionated radiotherapy during a regional training course held in Malaysia in ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programmeThe patients received Lutetium (177Lu) rhPSMA-10.1 Injections at ...

Nuclear medicine uses radionuclides for imaging and therapeutic purposes. These unstable nuclei decay by emitting radiation, which will damage or destroy the cancer cells. Over th ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...